Catalyst Pharmaceuticals, Inc. CN2.F Stock
Catalyst Pharmaceuticals, Inc. Price Chart
Catalyst Pharmaceuticals, Inc. CN2.F Financial and Trading Overview
| Catalyst Pharmaceuticals, Inc. stock price | 14.99 EUR |
| Previous Close | 10.76 EUR |
| Open | 11.14 EUR |
| Bid | 11.2 EUR x 240700 |
| Ask | 11.43 EUR x 231600 |
| Day's Range | 11.14 - 11.14 EUR |
| 52 Week Range | 6.05 - 20.62 EUR |
| Volume | 219 EUR |
| Avg. Volume | 111 EUR |
| Market Cap | 1.22B EUR |
| Beta (5Y Monthly) | 1.09683 |
| PE Ratio (TTM) | 13.415663 |
| EPS (TTM) | 0.51 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.3 EUR |
CN2.F Valuation Measures
| Enterprise Value | 985.82M EUR |
| Trailing P/E | 13.415663 |
| Forward P/E | 20.245455 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.739321 |
| Price/Book (mrq) | 3.5349207 |
| Enterprise Value/Revenue | 3.844 |
| Enterprise Value/EBITDA | 7.709 |
Trading Information
Catalyst Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 1.09683 |
| 52-Week Change | 76.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 20.62 EUR |
| 52 Week Low | 6.05 EUR |
| 50-Day Moving Average | 13.64 EUR |
| 200-Day Moving Average | 14.57 EUR |
CN2.F Share Statistics
| Avg. Volume (3 month) | 111 EUR |
| Avg. Daily Volume (10-Days) | 29 EUR |
| Shares Outstanding | 106.08M |
| Float | 89.03M |
| Short Ratio | N/A |
| % Held by Insiders | 5.94% |
| % Held by Institutions | 82.71% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 38.75% |
| Operating Margin (ttm) | 46.81% |
| Gross Margin | 77.23% |
| EBITDA Margin | 49.86% |
Management Effectiveness
| Return on Assets (ttm) | 22.94% |
| Return on Equity (ttm) | 35.89% |
Income Statement
| Revenue (ttm) | 256.48M EUR |
| Revenue Per Share (ttm) | 2.47 EUR |
| Quarterly Revenue Growth (yoy) | 98.09% |
| Gross Profit (ttm) | 160.02M EUR |
| EBITDA | 127.89M EUR |
| Net Income Avi to Common (ttm) | 99.41M EUR |
| Diluted EPS (ttm) | 0.83 |
| Quarterly Earnings Growth (yoy) | 123.30% |
Balance Sheet
| Total Cash (mrq) | 148.25M EUR |
| Total Cash Per Share (mrq) | 1.4 EUR |
| Total Debt (mrq) | 3.81M EUR |
| Total Debt/Equity (mrq) | 1.14 EUR |
| Current Ratio (mrq) | 3.508 |
| Book Value Per Share (mrq) | 3.15 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 119.64M EUR |
| Levered Free Cash Flow (ttm) | -74171376 EUR |
Profile of Catalyst Pharmaceuticals, Inc.
| Country | Germany |
| State | FL |
| City | Coral Gables |
| Address | 355 Alhambra Circle |
| ZIP | 33134 |
| Phone | 305 420 3200 |
| Website | https://www.catalystpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 82 |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Q&A For Catalyst Pharmaceuticals, Inc. Stock
What is a current CN2.F stock price?
Catalyst Pharmaceuticals, Inc. CN2.F stock price today per share is 14.99 EUR.
How to purchase Catalyst Pharmaceuticals, Inc. stock?
You can buy CN2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Catalyst Pharmaceuticals, Inc.?
The stock symbol or ticker of Catalyst Pharmaceuticals, Inc. is CN2.F.
Which industry does the Catalyst Pharmaceuticals, Inc. company belong to?
The Catalyst Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Catalyst Pharmaceuticals, Inc. have in circulation?
The max supply of Catalyst Pharmaceuticals, Inc. shares is 124.5M.
What is Catalyst Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Catalyst Pharmaceuticals, Inc. PE Ratio is 29.38235300 now.
What was Catalyst Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Catalyst Pharmaceuticals, Inc. EPS is 0.51 EUR over the trailing 12 months.
Which sector does the Catalyst Pharmaceuticals, Inc. company belong to?
The Catalyst Pharmaceuticals, Inc. sector is Healthcare.